Dysregulated glucose metabolism in the brain is considered to be one of the key causes of Alzheimer’s disease (AD). Abnormal glucose uptake in AD is tightly associated with decreased levels of glucose transporter 1 (GLUT1) and GLUT3 in the brain, but the underlying mechanisms remain unclear.
Objective:
We aimed to explore the cause and mechanism of impaired glucose uptake in AD.
Methods:
N2a/WT and N2a/APP695swe cells were cultured in vitro, and cellular glucose uptake and ATP content, as well as the expression of GLUT1, GLUT3, and PI3K/Akt pathway members, were detected. Intracellular reactive oxygen species (ROS) levels were detected by flow cytometry. After treatment with the ROS scavenger N-acetyl-L-cysteine (NAC), the above indicators were detected again.
Results:
GLUT1 expression was significantly decreased (p = 0.0138) in N2a/APP695swe cells, while GLUT3 expression was no statistical difference (p > 0.05). After NAC treatment, PI3K and Akt phosphorylation levels, GLUT1 expression, glucose uptake and ATP levels were remarkably increased (p = 0.0006, p = 0.0008, p = 0.0009, p = 0.0001, p = 0.0013), while Aβ levels were significantly decreased (p = 0.0058, p = 0.0066). After addition of the PI3K inhibitor LY29004, GLUT1 expression was reduced (p = 0.0008), and Aβ levels were increased (p = 0.0009, p = 0.0117). In addition, increases in glucose uptake and ATP levels induced by the Akt activator SC79 were hindered by the GLUT1 inhibitor WZB117 (p = 0.0002, p = 0.0005). Aβ levels were decreased after SC79 treatment and increased after WZB117 treatment (p = 0.0212, p = 0.0006).
Conclusion:
Taken together, scavenging of ROS prevents from Aβ deposition via activation of the PI3K/Akt/GLUT1 pathway, and improved the impaired glucose uptake in N2a/APP695swe cells.
CalabroM, RinaldiC, SantoroG, CrisafulliC (2021) The biological pathways of Alzheimer disease: A review. AIMS Neurosci8, 86–132.
2.
WangJ, GuBJ, MastersCL, WangYJ (2017) A systemic view of Alzheimer disease - insights from amyloid-beta metabolism beyond the brain. Nat Rev Neurol13, 612–623.
3.
DemetriusLA, DriverJ (2013) Alzheimer’s as a metabolic disease. Biogerontology14, 641–649.
4.
Campos-PenaV, Toral-RiosD, Becerril-PerezF, Sanchez-TorresC, Delgado-NamoradoY, Torres-OssorioE, Franco-BocanegraD, CarvajalK (2017) Metabolic syndrome as a risk factor for Alzheimer’s disease: Is abeta a crucial factor in both pathologies? . Antioxid Redox Signal26, 542–560.
5.
de la Monte SM, TongM (2014) Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem Pharmacol88, 548–559.
6.
Pujol-GimenezJ, MartisovaE, Perez-MediavillaA, LostaoMP, RamirezMJ (2014) Expression of the glucose transporter GLUT12 in Alzheimer’s disease patients. J Alzheimers Dis42, 97–101.
7.
MosconiL, De Santi S, LiJ, TsuiWH, LiY, BoppanaM, LaskaE, RusinekH, de Leon MJ (2008) Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging29, 676–692.
8.
ChenZ, ZhongC (2013) Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. Prog Neurobiol108, 21–43.
9.
LeeYJ, KimJE, HwangIS, KwakMH, LeeJH, JungYJ, AnBS, KwonHS, KimBC, KimSJ, KimJM, HwangDY (2013) Alzheimer’s phenotypes induced by overexpression of human presenilin 2 mutant proteins stimulate significant changes in key factors of glucose metabolism. Mol Med Rep7, 1571–1578.
Llanos-GonzalezE, Henares-ChavarinoAA, Pedrero-PrietoCM, Garcia-CarpinteroS, Frontinan-RubioJ, Sancho-BielsaFJ, AlcainFJ, PeinadoJR, Rabanal-RuizY, Duran-PradoM (2020) Interplay between mitochondrial oxidative disorders and proteostasis in Alzheimer’s disease. Front Neurosci13, 1444.
15.
PopracP, JomovaK, SimunkovaM, KollarV, RhodesCJ, ValkoM (2017) Targeting free radicals in oxidative stress-related human diseases. Trends Pharmacol Sci38, 592–607.
16.
ChenYY, WangMC, WangYN, HuHH, LiuQQ, LiuHJ, ZhaoYY (2020) Redox signaling and Alzheimer’s disease: From pathomechanism insights to biomarker discovery and therapy strategy. Biomark Res8, 42.
17.
AverySV (2011) Molecular targets of oxidative stress. Biochem J434, 201–210.
18.
LiH, LanJ, WangG, GuoK, HanC, LiX, HuJ, CaoZ, LuoX (2020) KDM4B facilitates colorectal cancer growth and glucose metabolism by stimulating TRAF6-mediated AKT activation. J Exp Clin Cancer Res39, 12.
19.
PerluigiM, PupoG, TramutolaA, CiniC, CocciaR, BaroneE, HeadE, ButterfieldDA, Di DomenicoF (2014) Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim Biophys Acta1842, 1144–1153.
20.
AliT, KimT, RehmanSU, KhanMS, AminFU, KhanM, IkramM, KimMO (2018) Natural dietary supplementation of anthocyanins via PI3K/Akt/Nrf2/HO-1 pathways mitigate oxidative stress, neurodegeneration, and memory impairment in a mouse model of Alzheimer’s disease. Mol Neurobiol55, 6076–6093.
21.
GrantCM, QuinnKA, DawesIW (1999) Differential protein S-thiolation of glyceraldehyde-3-phosphate dehydrogenase isoenzymes influences sensitivity to oxidative stress. Mol Cell Biol19, 2650–2656.
PeiL, KongY, ShaoC, YueX, WangZ, ZhangN (2018) Heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to pharmorubicin by promoting autophagy via PI3K/Akt pathway. J Cell Mol Med22, 5311–5321.
24.
LiuF, WuX, JiangX, QianY, GaoJ (2018) Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3beta/beta-catenin signalling. J Exp Clin Cancer Res37, 122.
25.
LiuY, CaoY, ZhangW, BergmeierS, QianY, AkbarH, ColvinR, DingJ, TongL, WuS, HinesJ, ChenX (2012) A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth and.} }. Mol Cancer Ther11, 1672–1682.
26.
JoH, MondalS, TanD, NagataE, TakizawaS, SharmaAK, HouQ, ShanmugasundaramK, PrasadA, TungJK, TejedaAO, ManH, RigbyAC, LuoHR (2012) Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death. Proc Natl Acad Sci U S A109, 10581–10586.
27.
WangX, WangW, LiL, PerryG, LeeHG, ZhuX (2014) Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta1842, 1240–1247.
28.
SzablewskiL (2017) Glucose transporters in brain:, In health and in Alzheimer’s disease, J Alzheimers Dis55, 1307–1320.
AllenA, MessierC (2013) Plastic changes in the astrocyte GLUT1 glucose transporter and beta-tubulin microtubule protein following voluntary exercise in mice. Behav Brain Res240, 95–102.
KumariU, HeeseK (2010) Cardiovascular dementia - a different perspective. Open Biochem J4, 29–52.
33.
MarkRJ, PangZ, GeddesJW, UchidaK, MattsonMP (1997) Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: Involvement of membrane lipid peroxidation. J Neurosci17, 1046–1054.
34.
KumarM, BansalN (2021) Implications of phosphoinositide 3-Kinase-Akt (PI3K-Akt) pathway in the pathogenesis of Alzheimer’s disease. Mol Neurobiol59, 354–385.
35.
ZhaoY, HuX, LiuY, DongS, WenZ, HeW, ZhangS, HuangQ, ShiM (2017) ROS signaling under metabolic stress: Cross-talk between AMPK and AKT pathway. Mol Cancer16, 79.
36.
De Strooper B, VassarR, GoldeT (2010) The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol6, 99–107.
Alvira-BoteroX, CarroEM (2010) Clearance of amyloid-beta peptide across the choroid plexus in Alzheimer’s disease. Curr Aging Sci3, 219–229.
39.
SelkoeDJ (2001) Clearing the brain’s amyloid cobwebs. Neuron32, 177–180.
40.
TanziRE, MoirRD, WagnerSL (2004) Clearance of Alzheimer’s Abeta peptide: The many roads to perdition. Neuron43, 605–608.
41.
WaliaV, KaushikD, MittalV, KumarK, VermaR, ParasharJ, AkterR, RahmanMH, BhatiaS, Al-HarrasiA, KarthikaC, BhattacharyaT, ChopraH, AshrafGM (2021) Delineation of neuroprotective effects and possible benefits of antioxidantstherapy for the treatment of Alzheimer’s diseases by targeting mitochondrial-derived reactive oxygen species: Bench to bedside. Mol Neurobiol59, 657–680.
